Moderna company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
In remarks tied to its latest earnings discussion, Moderna indicated it will hold to its 2026 growth target as it adjusts spending plans, while pushing forward programs across flu, oncology, and rare diseases toward upcoming milestone events.
THE APEX TIMES
THE APEX TIMES
The FDA clearance for Moderna’s mRNA-based flu shot, mFlusiva, expands the company’s influenza portfolio for older adults, but the market reaction was muted in Tuesday trading.
THE APEX TIMES
Moderna shares moved unevenly after the FDA approved the company’s mRNA-based flu vaccine, with traders weighing whether a regulatory win is enough to restart momentum.
THE APEX TIMES
The company’s mFlusiva, an mRNA-based shot, has received Food and Drug Administration approval for adults aged 50 and over, giving investors a new milestone in the push to build recurring seasonal vaccine demand.
THE APEX TIMES
A market wrap highlighted how expectations around memory and storage hardware can spill over into broader index sentiment, pulling some high-profile tech-adjacent winners into the day’s narrative.
THE APEX TIMES
The biotech said the U.S. Food and Drug Administration has approved what it calls its first influenza vaccine using messenger RNA technology, a milestone aimed at expanding mRNA beyond COVID-19.
THE APEX TIMES
The approval gives Moderna a new FDA-authorized product for seasonal flu, adding to a growing list of globally approved vaccines as the company looks to broaden its addressable market beyond COVID-19.
THE APEX TIMES
Even after a standout run for Moderna, a new Wall Street snapshot points to lingering caution about the stock’s longer-term direction, underscoring how fast expectations can shift in high-profile biotech.
THE APEX TIMES
A summary of Moderna, Inc.’s second-quarter 2026 earnings call circulated on a market-news feed on Aug. 1, yet the underlying figures and guidance details are not included in the information currently available for review.
